Bexarotene reverses alopecia in cutaneous T-cell lymphoma [1]

British Journal of Dermatology

Volumn 149, Issue 1, 2003, Pages 193-196

  Hanson, M ^a   Hill, A ^a   Duvic, M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CD4 ANTIGEN; CD8 ANTIGEN; MUCIN;

ADULT; AGED; ALOPECIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; FEMALE; GENERAL CONDITION IMPROVEMENT; HAIR GROWTH; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PUVA; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 0042134625     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05399.x     Document Type: Letter

References (12)

1. Jackow CM, Papadopoulos E, Nelson B et al. Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor Vbeta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides? J Am Acad Dermatol 1997; 37: 828-31.
2. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002; 138: 191-8.
3. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
4. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.
5. Zhang C, Hazarika P, Ni X et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8: 1234-40.
6. Thein C, Strange P, Hansen ER, Baadsgaard O. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res 1997; 289: 384-8.
7. Welsh EA, Clark HH, Epstein SZ et al. HLA-DQB1*03 alleles are associated with alopecia areata. J Invest Dermatol 1994; 103: 758-63.
8. Jackow CM, McHam JB, Friss A et al. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol 1996; 107: 373-6.
9. De Panfilis G. 'Activation-induced cell death': a special program able to preserve the homeostasis of the skin? Exp Dermatol 2002; 11: 1-11.
10. Boehm MF, Zhang L, Zhi L et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146-55.
11. Cheng S, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 649-52.
12. Breneman D, Duvic M, Kuzel T et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-32.